Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 4Active not recruiting 3Unknown 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 62Gastrointestinal 11CNS 5Gynecologic 4Thoracic 3Other solid neoplasm 3Tumor-Agnostic 2Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Solid Tumors 2Malignant Solid Neoplasm 1

Interventions

pembrolizumab 27Nivolumab 11Pemetrexed 10Cyclophosphamide 10Carboplatin 10atezolizumab 9Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6Injections 5tislelizumab 4spartalizumab 4fludarabine 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2tocilizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Trastuzumab × Other solid neoplasm × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

NCT06136897 2026-04-13

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡